2023: Estimating the prevalence of poor-quality anti-TB medicines

Tuberculosis (TB) remains a major global public health problem, especially with the recent emergence of multidrug-resistant TB and extensively drug-resistant TB. There has been little consideration of the extent of substandard and falsified (SF) TB medicines as drivers of resistance. We assessed the evidence on the prevalence of SF anti-TB medicines and discussed their public health impact. Full paper see here: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10347509/pdf/bmjgh-2023-012039.pdf

« back